Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Voltage-gated L-type calcium channel alpha-1D subunit | Starlite/ChEMBL | References |
Oryctolagus cuniculus | Voltage-gated L-type calcium channel alpha-1C subunit | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0384 | 0.8983 | 0.8983 |
Loa Loa (eye worm) | hypothetical protein | 0.0384 | 0.8983 | 0.8983 |
Echinococcus granulosus | voltage dependent calcium channel | 0.0186 | 0.3413 | 0.3749 |
Brugia malayi | Fibronectin type III domain containing protein | 0.0388 | 0.9102 | 0.8637 |
Loa Loa (eye worm) | TK/KIN16 protein kinase | 0.042 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0388 | 0.9102 | 0.9102 |
Echinococcus granulosus | voltage dependent L type calcium channel subunit|voltage dependent calcium channel | 0.0186 | 0.3413 | 0.3749 |
Trypanosoma brucei | Voltage-dependent calcium channel subunit, putative | 0.0065 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0384 | 0.8983 | 0.8983 |
Loa Loa (eye worm) | hypothetical protein | 0.0186 | 0.3413 | 0.3413 |
Toxoplasma gondii | transporter, cation channel family protein | 0.0065 | 0 | 0.5 |
Echinococcus granulosus | defective proboscis extension response | 0.0384 | 0.8983 | 0.9869 |
Loa Loa (eye worm) | hypothetical protein | 0.0384 | 0.8983 | 0.8983 |
Loa Loa (eye worm) | hypothetical protein | 0.0388 | 0.9102 | 0.9102 |
Echinococcus granulosus | neuroglian | 0.0384 | 0.8983 | 0.9869 |
Loa Loa (eye worm) | hypothetical protein | 0.0384 | 0.8983 | 0.8983 |
Schistosoma mansoni | nephrin | 0.0388 | 0.9102 | 0.9827 |
Loa Loa (eye worm) | calcium channel | 0.0186 | 0.3413 | 0.3413 |
Echinococcus granulosus | neurotracting:lsamp:neurotrimin:obcam | 0.0384 | 0.8983 | 0.9869 |
Echinococcus multilocularis | roundabout 2 | 0.0388 | 0.9102 | 1 |
Echinococcus granulosus | Immunoglobulin | 0.0384 | 0.8983 | 0.9869 |
Schistosoma mansoni | defective proboscis extension response (dpr)-related | 0.0384 | 0.8983 | 0.962 |
Brugia malayi | hypothetical protein | 0.0388 | 0.9102 | 0.8637 |
Echinococcus multilocularis | Immunoglobulin | 0.0384 | 0.8983 | 0.979 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0388 | 0.9102 | 0.8637 |
Schistosoma mansoni | vesicular amine transporter | 0.0392 | 0.9203 | 1 |
Echinococcus granulosus | roundabout 2 | 0.0388 | 0.9102 | 1 |
Echinococcus granulosus | voltage dependent calcium channel type d subunit|voltage dependent calcium channel|voltage dependent L type calcium channel subu | 0.0186 | 0.3413 | 0.3749 |
Schistosoma mansoni | cell adhesion molecule | 0.0388 | 0.9102 | 0.9827 |
Echinococcus granulosus | twitchin | 0.0384 | 0.8983 | 0.9869 |
Trypanosoma cruzi | Voltage-dependent calcium channel subunit, putative | 0.0065 | 0 | 0.5 |
Echinococcus multilocularis | basement membrane specific heparan sulfate | 0.0384 | 0.8983 | 0.979 |
Loa Loa (eye worm) | hypothetical protein | 0.0388 | 0.9102 | 0.9102 |
Schistosoma mansoni | Neurotrimin precursor (hNT) | 0.0384 | 0.8983 | 0.962 |
Loa Loa (eye worm) | hypothetical protein | 0.0384 | 0.8983 | 0.8983 |
Echinococcus multilocularis | neuroglian | 0.0384 | 0.8983 | 0.979 |
Echinococcus multilocularis | Immunoglobulin | 0.0384 | 0.8983 | 0.979 |
Echinococcus granulosus | voltage dependent calcium channel type d subunit|voltage dependent calcium channel alpha 1 | 0.0186 | 0.3413 | 0.3749 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.4 uM | Antagonist activity at rat CaV1.3alpha1D transfected in HEK293 cells by FLIPR assay | ChEMBL. | 23651412 |
IC50 (binding) | = 2.6 uM | Antagonist activity at rabbit CaV1.2alpha1C transfected in HEK293 cells by FLIPR assay | ChEMBL. | 23651412 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.